Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Omar Nadeem, M.D.

Title
Institution
Department
Address

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Cowan A, Ferrari F, Freeman SS, Redd R, El-Khoury H, Perry J, Patel V, Kaur P, Barr H, Lee DJ, Lightbody E, Downey K, Argyelan D, Theodorakakou F, Fotiou D, Liacos CI, Kanellias N, Chavda SJ, Ainley L, Sandecká V, Pospíšilová L, Minarik J, Jungova A, Radocha J, Spicka I, Nadeem O, Yong K, Hájek R, Kastritis E, Marinac CR, Dimopoulos MA, Get G, Trippa L, Ghobrial IM. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study. Lancet Haematol. 2023 Mar; 10(3):e203-e212. PMID: 36858677; PMCID: PMC9991855.
    Citations:    Fields:    Translation:Humans
  2. Dutta AK, Alberge JB, Lightbody ED, Boehner CJ, Dunford A, Sklavenitis-Pistofidis R, Mouhieddine TH, Cowan AN, Su NK, Horowitz EM, Barr H, Hevenor L, Beckwith JB, Perry J, Cao A, Lin Z, Kuhr FK, Mastro RGD, Nadeem O, Greipp PT, Stewart C, Auclair D, Getz G, Ghobrial IM. MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology. Cancer Discov. 2023 Feb 06; 13(2):348-363. PMID: 36477267.
    Citations:    Fields:    Translation:HumansCells
  3. Sklavenitis-Pistofidis R, Aranha MP, Redd RA, Baginska J, Haradhvala NJ, Hallisey M, Dutta AK, Savell A, Varmeh S, Heilpern-Mallory D, Ujwary S, Zavidij O, Aguet F, Su NK, Lightbody ED, Bustoros M, Tahri S, Mouhieddine TH, Wu T, Flechon L, Anand S, Rosenblatt JM, Zonder J, Vredenburgh JJ, Boruchov A, Bhutani M, Usmani SZ, Matous J, Yee AJ, Jakubowiak A, Laubach J, Manier S, Nadeem O, Richardson P, Badros AZ, Mateos MV, Trippa L, Getz G, Ghobrial IM. Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer Cell. 2022 11 14; 40(11):1358-1373.e8. PMID: 36379208; PMCID: PMC10019228.
    Citations: 1     Fields:    Translation:Humans
  4. O'Donnell EK, Shapiro YN, Yee AJ, Nadeem O, Laubach JP, Branagan AR, Anderson KC, Mo CC, Munshi NC, Ghobrial IM, Sperling AS, Agyemang EA, Burke JN, Harrington CC, Hu BY, Richardson PG, Raje NS, El-Jawahri A. Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma. Blood Adv. 2022 09 13; 6(17):4967-4974. PMID: 35848842; PMCID: PMC9631626.
    Citations:    Fields:    Translation:Humans
  5. Nadeem O, Mateos MV, Efebera YA, Paner A, Larocca A, Rodríguez-Otero P, Leleu X, Richardson PG. Melphalan flufenamide for relapsed/refractory multiple myeloma. Drugs Today (Barc). 2022 Aug; 58(8):407-423. PMID: 35983927.
    Citations:    Fields:    Translation:Humans
  6. Ocio EM, Nadeem O, Schjesvold F, Gay F, Touzeau C, Dimopoulos MA, Richardson PG, Mateos MV. Melflufen for the treatment of multiple myeloma. Expert Rev Clin Pharmacol. 2022 Apr; 15(4):371-382. PMID: 35723075.
    Citations:    Fields:    Translation:Animals
  7. Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, Medvedova E, McCarthy PL, Libby EN, Voorhees PM, Orlowski RZ, Anderson LD, Zonder JA, Milner CP, Gasparetto C, Agha ME, Khan AM, Hurd DD, Gowin K, Kamble RT, Jagannath S, Nathwani N, Alsina M, Cornell RF, Hashmi H, Campagnaro EL, Andreescu AC, Gentile T, Liedtke M, Godby KN, Cohen AD, Openshaw TH, Pasquini MC, Giralt SA, Kaufman JL, Yee AJ, Scott E, Torka P, Foley A, Fulciniti M, Hebert K, Samur MK, Masone K, Maglio ME, Zeytoonjian AA, Nadeem O, Schlossman RL, Laubach JP, Paba-Prada C, Ghobrial IM, Perrot A, Moreau P, Avet-Loiseau H, Attal M, Anderson KC, Munshi NC. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med. 2022 07 14; 387(2):132-147. PMID: 35660812.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  8. O'Donnell EK, Shapiro YN, Yee AJ, Nadeem O, Hu BY, Laubach JP, Branagan AR, Anderson KC, Mo CC, Munshi NC, Ghobrial IM, Sperling AS, Agyemang EA, Burke JN, Harrington CC, Richardson PG, Raje NS, El-Jawahri A. Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma. Cancer. 2022 05 15; 128(10):1996-2004. PMID: 35167125.
    Citations: 2     Fields:    Translation:Humans
  9. Larocca A, Leleu X, Touzeau C, Bladé J, Paner A, Mateos MV, Cavo M, Maisel C, Alegre A, Oriol A, Raptis A, Rodriguez-Otero P, Mazumder A, Laubach J, Nadeem O, Sandberg A, Orre M, Torrång A, Bakker NA, Richardson PG. Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study. Br J Haematol. 2022 02; 196(3):639-648. PMID: 34671975; PMCID: PMC9135124.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  10. Jagannath S, Mikhael J, Nadeem O, Raje N. Digital Health for Patients With Multiple Myeloma: An Unmet Need. JCO Clin Cancer Inform. 2021 10; 5:1096-1105. PMID: 34735265.
    Citations: 4     Fields:    Translation:HumansCellsPHPublic Health
  11. Louvet C, Nadeem O, Smith EL. Finding the optimal partner to pair with bispecific antibody therapy for multiple myeloma. Blood Cancer Discov. 2021 Jul; 2(4):297-299. PMID: 34258583; PMCID: PMC8265983.
    Citations: 2     Fields:    
  12. Sewastianik T, Straubhaar JR, Zhao JJ, Samur MK, Adler K, Tanton HE, Shanmugam V, Nadeem O, Dennis PS, Pillai V, Wang J, Jiang M, Lin J, Huang Y, Brooks D, Bouxsein M, Dorfman DM, Pinkus GS, Robbiani DF, Ghobrial IM, Budnik B, Jarolim P, Munshi NC, Anderson KC, Carrasco RD. miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms. Blood. 2021 04 08; 137(14):1905-1919. PMID: 33751108; PMCID: PMC8033455.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  13. Nadeem O, Richardson PG. The initial management of multiple myeloma in the era of novel agents: 2021 and beyond. Br J Haematol. 2021 04; 193(2):213-215. PMID: 33748954.
    Citations:    Fields:    Translation:Humans
  14. Tuazon SA, Holmberg LA, Nadeem O, Richardson PG. A clinical perspective on plasma cell leukemia; current status and future directions. Blood Cancer J. 2021 02 04; 11(2):23. PMID: 33563906.
    Citations: 10     Fields:    Translation:HumansAnimals
  15. Richardson PG, Oriol A, Larocca A, Bladé J, Cavo M, Rodriguez-Otero P, Leleu X, Nadeem O, Hiemenz JW, Hassoun H, Touzeau C, Alegre A, Paner A, Maisel C, Mazumder A, Raptis A, Moreb JS, Anderson KC, Laubach JP, Thuresson S, Thuresson M, Byrne C, Harmenberg J, Bakker NA, Mateos MV. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. J Clin Oncol. 2021 03 01; 39(7):757-767. PMID: 33296242; PMCID: PMC8078327.
    Citations: 38     Fields:    Translation:HumansCTClinical Trials
  16. Nadeem O, Tai YT, Anderson KC. Immunotherapeutic and Targeted Approaches in Multiple Myeloma. Immunotargets Ther. 2020; 9:201-215. PMID: 33117743.
    Citations: 7     
  17. Nadeem O, Ghobrial IM. Intensification and consolidation therapy in multiple myeloma in the current era. Lancet Haematol. 2020 06; 7(6):e427-e429. PMID: 32359505.
    Citations:    Fields:    Translation:Humans
  18. Nadeem O, Anderson KC. The safety of current and emerging therapies for multiple myeloma. Expert Opin Drug Saf. 2020 Mar; 19(3):269-279. PMID: 32098519.
    Citations: 3     Fields:    Translation:Humans
  19. Levin SN, de Gusmao CM, Etherton MR, Will Rondeau M, Meredith DM, Folkerth RD, Klein JP, Nadeem O, Castillo JJ. "All the soarings of my mind begin in my blood:" central nervous system complication of Waldenström macroglobulinemia. Am J Hematol. 2016 Oct; 91(10):1057-60. PMID: 27414991.
    Citations:    Fields:    Translation:Humans
  20. Castillo JJ, Nadeem O. Improving the accuracy in prognosis for Burkitt lymphoma patients. Expert Rev Anticancer Ther. 2014 Feb; 14(2):125-7. PMID: 24329420.
    Citations: 1     Fields:    Translation:Humans
  21. Nadeem O, Gui J, Ornstein DL. Prevalence of venous thromboembolism in patients with secondary polycythemia. Clin Appl Thromb Hemost. 2013 Jul-Aug; 19(4):363-6. PMID: 23007895.
    Citations: 17     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Nadeem's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (73)
Explore
_
Co-Authors (35)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
© 2023 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.